Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
about
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedThe emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancerAnalysis of oncogenic signaling induced by tyrosine kinases in tumors by SILAC-based quantitative proteomic approachLarge granular lymphocytosis during dasatinib therapyDasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental SilicosisMechanisms of drug resistance in kinases.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE studyA genomic and evolutionary approach reveals non-genetic drug resistance in malariaRaf kinases in cancer-roles and therapeutic opportunitiesCombination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemiaOptimizing combination therapies with existing and future CML drugsA target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLHow bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public healthImatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategyConstitutive Activity in an Ancestral Form of Abl Tyrosine Kinase.A research-inspired laboratory sequence investigating acquired drug resistance.Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibTyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyBCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case ReportBCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemiaAnti-leukemia activity of a Hsp70 inhibitor and its hybrid moleculesThe burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysisA robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cellsA therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibAn update on dual Src/Abl inhibitors.Extensive gene-specific translational reprogramming in a model of B cell differentiation and Abl-dependent transformationPractical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling.Enantioselective synthesis of α-secondary and α-tertiary piperazin-2-ones and piperazines by catalytic asymmetric allylic alkylation.HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.
P2860
Q24299821-EA05F962-EC1C-4049-AFA5-0EFD700F8208Q26738514-ED2393B1-EA18-4C7E-B929-53EE70B6DE4FQ26751387-71A851CB-E019-49E6-A29F-94FF6208E77EQ26852884-3C10B11E-FCC8-461D-87C4-AE02A64C31B0Q27012699-D4C67348-B609-496E-ADAD-90DA825FDBA0Q27330347-ACCC9F0D-2B2B-4949-976C-0B4DA732D1ACQ27692567-C68184B4-4331-45C2-A27D-FB75D18457DEQ27851628-25034F8D-445E-46DC-A98D-F4D07DDF7A86Q27852657-8C2B0653-66BE-4FCA-B56A-97E1850233C0Q27861944-AD7F71C9-916B-48E5-872D-693667F0D9F8Q28237793-C03CB93E-AC69-417A-BDAE-EEBC49AA9035Q28474737-874EA9E3-0362-4F61-A754-5B0014610D80Q28475255-CEE4CFB7-9F13-4B4A-9F0B-CAA5CFBE74E1Q28534337-C2297C58-28E1-4678-B41D-55D425D72E81Q28649612-5F0F5851-E160-4710-9B68-20939AC12D13Q30008882-0DC74471-6925-4D4F-83E0-A4439A3457D0Q30009150-E7246F60-80B0-4077-87F8-12B36BF443FBQ30402618-6AD827B5-22CB-4D8F-AE9F-926C11AC7647Q33391185-02B4482F-C753-4C6F-BE4E-685CBF0A04A9Q33401256-D77FA926-431E-4992-81AA-C7F86878914FQ33476874-3BE72FB9-245F-4A99-BCE8-0417CCFB1C39Q33574738-D7674EB0-1200-4CE2-A582-1CE5BBD5D015Q33781191-B0857E1F-D173-43C1-9733-CC360DBCE28AQ33799516-7AA9084E-908E-427D-B771-DE5A0A29DBAFQ33837323-4D3F474B-2353-4D15-8D03-CBAA37747C22Q33854949-6212932A-D9FA-4373-92C0-FE2821F90CB7Q33918198-A3700247-C59D-4D25-9897-E92C39C7B9EAQ34016866-31D1C7F9-36AC-4287-886D-6DAA885925DFQ34082540-F6A5F2F7-A127-4F93-A337-D894A32AB846Q34119969-169E7DFF-B66F-4320-A740-44EE07FB7B30Q34170309-9902CB2C-0737-4684-9B36-D012FED6B350Q34210528-F845DA29-A311-4775-A202-85788B7B45A9Q34270677-E8B4C961-745F-4ECE-809D-7B2D187287CCQ34302309-443FFBD6-F0BB-4518-B4F1-3752E4E0DD53Q34417824-4E215DCC-6EB3-42F5-A571-E2F6AAEBAC60Q34763374-7419EAD7-921C-4D60-B8EA-3D9287FB9352Q34765081-3DCF0460-8BE4-4094-9693-0EB682F12102Q34850044-A5B9657E-48E8-4D5B-9698-8B78C4A3E10CQ34988013-F2D39AF1-388D-4A6B-A101-208B1310D3F0Q35037415-B34B4D77-C2EC-41DF-BEC9-6A7E5F343BA5
P2860
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@ast
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@en
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@nl
type
label
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@ast
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@en
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@nl
prefLabel
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@ast
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@en
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@nl
P2093
P356
P1476
Second generation inhibitors o ...... ant chronic myeloid leukaemia.
@en
P2093
Ellen Weisberg
James D Griffin
Paul W Manley
Sandra W Cowan-Jacob
P2888
P304
P356
10.1038/NRC2126
P407
P577
2007-05-01T00:00:00Z
P5875
P6179
1041504094